Healthcare / Drug Manufacturers - Specialty & GenericKOSDAQ
$4010.00
-190.00 (-4.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $384.1M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$87.2B
P/E
27.5x
↑EV/EBITDA
13.5x
↑ROE
8.3%
↑Gross Margin
14.0%
↓Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.4%
FCF CAGR
-32.2%
FCF margin
2.1%
FCF / Net income
0.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $108.41B · net income $3.67B · FCF $2.30B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $108.41B | $108.41B | $103.85B | $94.01B | $113.11B |
| Net Income | $3.67B | $3.67B | $3.58B | $1.80B | $-3.58B |
| EBITDA | $8.73B | $8.73B | $10.01B | $9.03B | $4.03B |
| EPS | 146.00 | 146.00 | 41.00 | 76.00 | -170.00 |
| Gross Margin | 14.0% | 14.0% | 14.3% | 14.9% | 11.3% |
| Operating Margin | 2.7% | 2.7% | 2.2% | 1.9% | -1.1% |
| Net Margin | 3.4% | 3.4% | 3.4% | 1.9% | -3.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.39 | 0.39 | 0.42 | 0.65 | 0.70 |
| Current Ratio | 1.17 | 1.17 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $2.30B | $2.30B | $384.1M | $-1.64B | $7.38B |
| Returns | |||||
| ROE | 8.3% | 8.3% | 8.7% | 5.2% | -10.8% |
| Valuation | |||||
| P/E | 27.47 | 27.47 | 90.85 | 62.04 | — |
| EV/EBITDA | 13.50 | 13.50 | 34.18 | 14.22 | 32.58 |
| P/B | 2.27 | 2.27 | 7.89 | 3.23 | 3.51 |
| Growth & Yield | |||||
| Revenue Growth | 4.4% | 4.4% | 10.5% | -16.9% | — |
| EPS Growth | 256.1% | 256.1% | -46.1% | 144.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
34.6%
EPS terminal req.
$355.82
Spread vs growth
221.5%
5Y implied EPS CAGR
24.1%
EPS terminal req.
$430.54
Spread vs growth
232.0%
10Y implied EPS CAGR
16.9%
EPS terminal req.
$693.39
Spread vs growth
239.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.6%
Start / end P/E
95.4x → 27.5x
EPS bridge
41.00 → 146.00
Residual
-182.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.